

PERSONAL INFORMATION **Thomas Hinz**

## WORK EXPERIENCE

April 2005- Present

**Head of Section Therapeutic Vaccines**

Paul Ehrlich Institute (Germany)

Responsibility for regulatory procedures related to therapeutic vaccines. Drug products include synthetic peptides, recombinant proteins, virus-like particles, in vitro transcribed mRNA, liposomal formulations, and cell-based products. Regulatory procedures include GMP inspections, assessment of CMC, preclinical, and clinical dossiers in clinical trial applications and centralized MAA. Further activities include national and EMA scientific advice.

January 1993-March 2005

**Postdoctoral Fellow and Research Group Leader**

Paul Ehrlich Institute (Germany)

Analyses of the T cell receptor repertoires in HIV patients, and in individuals suffering from haematological malignancies. Head of a research group studying apoptosis in T cells. Work was supported by a grant from the German Research Foundation (DFG).

## EDUCATION AND TRAINING

1988- 1992

**Ph.D. Thesis**

Institute of Microbiology and Molecular Biology, University of Giessen (Germany)

Analysis of cis- and trans-acting elements of the mitosis of *Saccharomyces cerevisiae*: The cell cycle gene CDC15 and the centromere of chromosome 6.

1983- 1988

**Diploma Thesis**

Faculty of Biology, University of Giessen (Germany)

Analysis of integration sites of the transposon Ty in the LYS2-gene of *Saccharomyces cerevisiae*

## ADDITIONAL INFORMATION

**Expertise**

Molecular biology, immunology, review of quality and nonclinical

**Publications**

(1) Mellor, J., Jiang, W., Funk, M., Rathjen, J., Barnes, C. A., Hinz, T., Hegemann, J. H., and Philippsen, P. (1990). CPF1, a yeast protein which functions in centromeres and promoters. *EMBO J.* 9: 4017.

(2) Hinz, T., Wesch, D., Friese, K., Arden, B., and Kabelitz, D. (1994). T cell receptor gamma delta repertoire in HIV-infected individuals. *Eur. J. Immunol.* 24: 3044.

(3) Kabelitz, D., Ackermann, T., Hinz, T., Davodeau, F., Band, H., Bonneville, M., Janssen, O., Arden, B., Schondelmaier, S. (1994). New monoclonal antibody (23D12) recognizing three different Vgamma elements of the human gamma delta T cell receptor. *J. Immunol.* 152: 3128.

(4) Hinz, T., Marx, S., Nerl, C., and Kabelitz, D. (1996). Clonal expansion of gamma delta T cells expressing two distinct T cell receptors. *Br. J. Haematol.* 94: 62.

(5) Kabelitz, D., Hinz, T., Dobbmeyer, T., Mentzel, U., Marx, S., Bohme, A., Arden, B., Rossol, R., and Hoelzer, D. (1997). Clonal expansion of Vgamma 3/Vdelta 3 expressing T cells in a HIV1/2 negative patient with CD4 T cell deficiency. *Br. J. Haematol.* 96: 266.

(6) Hinz, T., Wesch, D., Halary, F., Marx, S., Choudhary, A., Arden, B., Janssen, O., Bonneville, M., and Kabelitz, D. (1997). Identification of the complete expressed T-cell receptor Vgamma repertoire by flow cytometry.

*Int. Immunol.* 9: 1065.

- (7) Wesch, D., Hinz, T., and Kabelitz, D. (1998). Analysis of the T cell receptor Vgamma repertoire in healthy donors and HIV-1 infected individuals.  
Int. Immunol.10: 1067.
- (8) Kabelitz, D., Wesch, D., and Hinz, T. (1999). gamma delta T cell receptor usage and role in human diseases.  
Springer Semin. Immunopathol. 21: 55.
- (9) Hinz, T., Allam, A., Wesch, D., Schindler, D., Kabelitz, D. (2000). Cell surface expression of transrearranged Vgamma-Cbeta T cell receptor chains in healthy donors and ataxia telangiectasia patients.  
Br. J. Haematol 109: 201.
- (10) Hinz, T., and Kabelitz, D. (2000). Identification of the T-cell receptor alpha variable (TRAV) gene(s) in T-cell malignancies.  
J. Immunol. Meth. 246: 145.
- (11) Weidmann, E., Hinz, T., Klein, S., Schui, D.K., Harder, S., Kriener, S., Kabelitz, D., Hoelzer, D., Mitrou, P.S. (2000). Cytotoxic leukemic hepatosplenic gamma delta T-cell lymphoma following acute myeloid leukemia bearing two distinct gamma-chains of the T-cell receptor. Biologic and clinical features.  
Haematologica 85: 1024.
- (12) Boehrer, S., Hinz, T., Schui, D., Harder, S., Chow, K., Schneider, B., Hoelzer, D., Mitrou, P., Weidmann, E. (2001). T-large granular lymphocyte leukemia with natural killer cell-like activity and expression of two different alpha- and beta-T-cell receptor chains.  
Br. J. Haematol. 112: 201.
- (13) Hinz, T., Flindt, S., Marx, A., Janssen, O., Kabelitz, D. (2001). Inhibition of protein synthesis by the T cell receptor-inducible hTDAG51 gene product.  
Cell. Signal.13: 345.
- (14) Weidmann, E., Boehrer, S., Chow, K.U., Engels, K., Harder, L., Hinz, T., Janssen, O., Kriener, S., Rummel, M.J., Siebert, R., Kabelitz, D., Hansmann, M.L., Hoelzer, D., Mitrou, P.S. (2001). Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine.  
Onkologie, 24: 162.
- (15) Flindt, S., Meier-Noorden, M., Hinz, T. (2001). Differentiating vector-derived mRNA from contaminating DNA templates by inverse RT-PCR.  
Biotechniques 31: 1296.
- (16) Hinz, T., Weidmann, E., Kabelitz, D. (2001). Dual TCR-expressing T lymphocytes in health and disease.  
Int. Arch. Allergy Immunol. 125: 16.
- (17) Meier-Noorden, M., Flindt, S., Kalinke, U., Hinz, T. (2004). A CpG-rich bidirectional promoter induces the T cell death-associated gene 51 and downregulates an inversely oriented transcript during early T cell activation.  
Gene 338: 197.
- (18) Hinz, T., Buchholz, C.J., van der Stappen, T., Cichutek, K., Kalinke, U. (2006). Manufacturing and quality control of cell-based tumor vaccines: A scientific and a regulatory perspective.  
Journal of Immunotherapy 29: 465.
- (19) Scherer, J., Hinz T, Cichutek, K. (2008). Trends in der Impfstoffentwicklung. DNA- und zellbasierte Impfstoffe.  
Pharm. Unserer Zeit 37(1):86-92.
- (20) Salmikangas, P., Flory, E., Reinhardt, J., Hinz, T. and Maciulaitis, R. (2010). Regulatory requirements for clinical trials and marketing authorisation application for cell-based medicinal products.  
Bundesgesundheitsblatt 53(1):24-9.
- (21) Britten, C.M., Sing-Jasuja, H., Flamion, B., Hoos, A., Huber, C., Kallen, K.-J., Khleif, S.N., Kreiter, S., Nielsen, M., Rammensee, H.-G. Sahin, U., Hinz, T., Kalinke, U. (2013). The regulatory landscape for actively personalized cancer immunotherapies.

Nature Biotechnology 31: 880.

Projects

Memberships Cell-based Working Party (EMA)  
Member, 2005-2010

Raw materials for the production of cellular and gene transfer products Working Party (EDQM)  
Member, since 2012

Other Relevant Information